Open Targets Platform: supporting systematic drug-target identification and prioritisation.

Overview of the Open Targets Platform. (A) The Platform data model includes the entities targets, diseases and drugs. The relationships between the three entities is shown. (B) Annotation of biomedical entities is provided from 26 underlying data sources. (C) The target identification and prioritisation framework is based on evidence from 20 evidence sources providing target–disease relationships. EFO expansion allows for capture of further associations between targets and diseases/phenotypes. For each target–disease association, the underlying data sources that provide evidence are scored, and an overall scoring ranks targets associated with the disease. Targets are further prioritised based on additional key attributes including tractability, safety and expression. (D) Platform data is accessible via a user interface or programmatically via the EMBL-EBI FTP server, API endpoints or as downloads via Google Cloud. Abbreviations: D, disease/phenotype; Dr, drug; EFO, Experimental factor ontology; T, target.

Post-marketing pharmacovigilance analysis for Pazopanib. Significant adverse events associated with Pazopanib (CHEMBL477772), based on systematic analysis of all available FDA Adverse Event Reporting System. Analysis is displayed in the Open Targets Platform for all drugs with available data.

Target - disease evidence in the Open Targets Platform. Data sources are grouped by data type—left. Unique validated evidence available in each of the platform releases since April 2016 (16.04)—middle. Relevant changes in the most recent period are annotated in further detail—right. A full list of the data sources with references is found in Supplementary Table S2.

Enhanced user interface and new functionality. Platform interface redesign for PTGS2 target profile page. (A) Identifiers and links to other resources are provided at the top of the page. Target information widgets outline the available data (in blue). By clicking on a widget, the user is taken to that section. Sections can be rearranged by the user, allowing them to personalise their experience. (B) The ‘Known drugs’ widget takes the user to a sortable and filterable table including information on clinical candidates or approved drugs, sourced from ChEMBL (12). (C) The ‘Tractability’ section provides a druggability assessment by small molecule, antibody or other modality.